The concomitant use of oxycodone HCl with all cytochrome P450 3A4 inhibitors could cause a rise in oxycodone plasma concentrations, which could raise or lengthen adverse reactions and will cause probably lethal respiratory despair. Additionally, discontinuation of a concomitantly utilized cytochrome P450 3A4 inducer may possibly result in a rise in